Semnur Pharmaceuticals, Inc. (SMNR)
OTCMKTS · Delayed Price · Currency is USD
8.00
0.00 (0.00%)
At close: Feb 23, 2026
Semnur Pharmaceuticals Company Description
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study.
The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Semnur Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Pharmaceutical Preparations |
| Employees | 10 |
| CEO | Jaisim Shah |
Contact Details
Address: 960 San Antonio Road Palo Alto, California 94303 United States | |
| Phone | 650-422-7515 |
| Website | semnurpharma.com |
Stock Details
| Ticker Symbol | SMNR |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jaisim Shah | Chief Executive Officer |
| Stephen Ma | Chief Financial Officer |